| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7ddc4774cf5f8a0bda44a780d73c53d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-282
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2826
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2873 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 |
| filingDate |
2020-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46145eb77da404a759fe73bb4dc6bc44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61a3c23e4299885994f97926e4d35df5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_268bb120655e52d7313424005f6554a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e2b7d1db58da4f921c80fee3119a3d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8288768ccd393a58b986e9e550e4add6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6dc61b9eb0b6d252f865e61154c1855f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8832a30334c5764161c6a6656b7eb986 |
| publicationDate |
2021-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-113597302-A |
| titleOfInvention |
A pharmaceutical composition comprising esomeprazole or a pharmaceutically acceptable salt thereof and having dual release properties |
| abstract |
The present invention relates to a pharmaceutical composition comprising esomeprazole or a pharmaceutically acceptable salt thereof and having dual release properties, in particular to a pharmaceutical composition that exhibits both an immediate release tablet release and a sustained release tablet release The release pattern of the pharmaceutical composition to maintain the efficacy for a long time. The dual-release characteristic pharmaceutical composition comprising esomeprazole or a pharmaceutically acceptable salt thereof in the present invention can ensure the same bioavailability as the existing esomeprazole immediate-release enteric-coated formulation, even if taken once a day It also maintains the drug effect for a long time due to the dual release mode, which can prevent the occurrence of acid breakthrough at night, so it can be effectively used as a therapeutic agent for acid breakthrough at night. |
| priorityDate |
2019-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |